Apanel of eight experts will debate treatment options for Peyronie’s disease during a 50-minute Prime Time plenary presentation Sunday morning titled Survivor Debate: Peyronie’s Disease, which begins at 10:40 am in the Esplanade Ballroom at Moscone South.
It’s estimated that Peyronie’s disease affects between 1 percent and 23 percent of men 40 to 70 years old.
“Peyronie’s is a relatively common condition in men where, as a result of various types of factors, plaque or scar tissue develops that can lead to problems with erection, penile curvature, penile pain and changes in the overall size or shape of the penis,” explained Lawrence Hakim, MD, FACS, Chairman of the Department of Urology and Director of the Center of Surgical Services at Cleveland Clinic Florida. “Peyronie’s disease often leads to patients and their partners being unable to have any type of intercourse or comfortable sexual relations.”
Dr. Hakim was a member of the panel that published the 2015 AUA guideline on Peyronie’s disease. The panel recommended that clinicians document the signs and symptoms that characterize Peyronie’s disease; take a careful history to assess penile deformity, interference with intercourse, penile pain and/or distress; and perform a physical exam of the genitalia.
Choosing the best treatment option is less straightforward, said Dr. Hakim, one of the session’s debaters.
While nonsteroidal anti-inflammatory drugs may be useful in alleviating the pain and phosphodiesterase type 5 inhibitors may improve erectile rigidity, there’s currently no oral medication that’s efficacious for treating the penile plaque, curvature or deformity of Peyronie’s disease, Dr. Hakim said. However, there are a variety of effective treatments available ranging from intralesional injections to surgery.
“Part of the debate about Peyronie’s disease is that there are a lot of alternative therapies that have been suggested, from topical medications and lithotripsy to radiation therapy, many of which have been shown to be not only ineffective, but potentially dangerous. They can make the situation worse,” Dr. Hakim said.
AUA guidelines recommend that clinicians discuss all available treatment options for Peyronie’s disease with patients, and the known risks and burdens associated with each therapy. The Survivor’s Debate format will help clinicians do just that.
During the session, each speaker will discuss a different treatment area, including the use of intralesional injection therapy with medications such as collagenase and interferon, external tools like traction devices and different surgical options. At the end of the session, attendees will vote on the most compelling speaker and treatment strategy.
Dr. Hakim will be joined in the debate by Martin Gelbard, MD, of UCLA School of Medicine; Run Wang, MD, FACS, of the University of Texas McGovern Medical School at Houston; Laurence Levine, MD, of Rush University Medical Center; Wayne Hellstrom, MD, FACS, of Tulane University School of Medicine; Rafael Carrion, MD, of the University of South Florida; Gerald Brock, MD, FRCSC, of Western University CANADA; and Steve Wilson, MD, FACS, FRCS, of the University of Arkansas for Medical Sciences.
“I hope attendees will realize that Peyronie’s disease is a very common and disabling condition for a lot of men,” Dr. Hakim said. “There are many different effective treatment options available depending on the individual’s situation. Physicians need to understand and communicate to their patients the advantages and disadvantages associated with the appropriate therapeutic alternatives in order to maximize their chances for success.”